Indian Pharma Market to Grow by 12-14% Up to 2023
The USD 41 billion Indian pharma industry, the world’s third largest by volume and 13th largest by value, stands to grow by between 12 and 14 percent in the next…
Address: First Floor, Su Motor Complex,, Veena Nagar, Mulund West, Mumbai-400 080,India
Tel: 022 30781000
Web: http://truecare.in/Truecare/
Abbott is a diverse global health care company with scientific expertise and products that address the varied healthcare needs of the people.
Abbott has been present in India for over 100 years now starting operations in 1910. The company’s pharmaceutical offerings expanded significantly over the years through organic growth and acquisitions. Currently Abbott is India’s largest pharmaceutical company in 2010 with the acquisition of Knoll, Solvay pharmaceuticals and Piramal Healthcare (domestic formulations division)
The product portfolio in India can be categorized into three broad categories – Pharmaceuticals, Nutrition and Medical devices.
Abbott serves the evolving healthcare needs of Indian consumers by introducing products backed by strong R&D. In addition our Established Pharmaceuticals Division (EPD) offers an expanding portfolio of branded generic drugs.
Our global citizenship priorities address the principal economic, social and environmental challenges necessary for a healthy society and a favorable business environment.
With over 13,000 people, India is Abbott’s largest employee base outside the United States. The company seeks to attract, retain and develop the best talent to ensure a healthy, safe, fulfilling work environment for all employees in India.
The product portfolio in India can be categorized into three broad categories – Pharmaceuticals, Nutrition and Medical devices.
Abbott serves the evolving healthcare needs of Indian consumers by introducing products backed by strong R&D. In addition our Established Pharmaceuticals Division (EPD) offers an expanding portfolio of branded generic drugs.
Our global citizenship priorities address the principal economic, social and environmental challenges necessary for a healthy society and a favorable business environment.
The USD 41 billion Indian pharma industry, the world’s third largest by volume and 13th largest by value, stands to grow by between 12 and 14 percent in the next…
Six Indian pharma and biotech firms have joined the global race to develop a vaccine for COVID-19 with India-developed vaccine candidates moving swiftly toward Phase I and II human trials…
COVID-19 restrictions have severely hampered multinational pharma companies who rely on India for generics and active pharmaceutical ingredients for the last month. With restrictions beginning to ease up, some manufacturing…
A recent IQVIA report highlights the increasing importance of Indian firms to the USA’s burgeoning generic pharmaceuticals market. Now accounting for over 90 percent of all prescriptions dispensed in…
The ongoing coronavirus outbreak and the subsequent shutdown of factories in China is having severe repercussions for Indian pharma manufacturers and could lead to global shortages. Shortages and Price…
Below is a selection of the top stories in Indian pharma from recent months, ranging from efforts to counter the coronavirus, to regulatory reform, the spike in USFDA warning letters…
Biocon, the first Indian company to have a biosimilar drug approved in the US, is taking another step forward with a new manufacturing facility and an expansion into the Australia…
The state of Gujarat proudly stands as India’s main pharmaceutical hub, accounting for over 33 percent of the country’s pharmaceutical turnover and 28 percent of its pharmaceutical exports. Given the…
Unlike many of his pharma peers, Vivek Sharma worked in operations and finance for two decades before joining the life sciences industry as head of Piramal Pharma Solutions (PPS) in…
The pharmaceutical industries of China and India, historically focused on their large domestic markets and exports to developed nations, are increasingly forging closer links. With US trade tariffs affecting both…
Aditya Bhattacharji is Healthcare Practice Head at Eurasia Group. In this article, he looks at India’s ambitious healthcare insurance scheme, “Modicare” and delves into some of its critical challenges and associated…
Dilip Shah, the Secretary-General of the Indian Pharmaceutical Alliance advocates for a stronger and more empowered regulator in India if the country is to build public confidence in its pharma output…
See our Cookie Privacy Policy Here
